This approach was inspired by two previous low-dose strategies, which showed that targeting four nodes of MAPK pathway in EGFR-mutant lung cancer cells, or combining PI3K, mTOR and MEK inhibitors in clear cell ovarian cancer cells, enabled penetrant pathway inhibition at drug doses that were well-tolerated in animal models (25,26). This evidence concerns the gene EGFR and ovarian clear cell cancer.